Antiviral type III CRISPR signalling via conjugation of ATP and SAM.

Chi, Haotian; Hoikkala, Ville; Grüschow, Sabine; Graham, Shirley; Shirran, Sally; White, Malcolm F · Nature · 2023

basic_science · Level V

Where this comes from

Abstract

CRISPR systems are widespread in the prokaryotic world, providing adaptive immunity against mobile genetic elements<sup>1,2</sup>. Type III CRISPR systems, with the signature gene cas10, use CRISPR RNA to detect non-self RNA, activating the enzymatic Cas10 subunit to defend the cell against mobile genetic elements either directly, via the integral histidine-aspartate (HD) nuclease domain<sup>3-5</sup> or indirectly, via synthesis of cyclic oligoadenylate second messengers to activate diverse ancillary effectors<sup>6-9</sup>. A subset of type III CRISPR systems encode an uncharacterized CorA-family membrane protein and an associated NrN family phosphodiesterase that are predicted to function in antiviral defence. Here we demonstrate that the CorA-associated type III-B (Cmr) CRISPR system from Bacteroides fragilis provides immunity against mobile genetic elements when expressed in Escherichia coli. However, B. fragilis Cmr does not synthesize cyclic oligoadenylate species on activation, instead generating S-adenosyl methionine (SAM)-AMP (SAM is also known as AdoMet) by conjugating ATP to SAM via a phosphodiester bond. Once synthesized, SAM-AMP binds to the CorA effector, presumably leading to cell dormancy or death by disruption of the membrane integrity. SAM-AMP is degraded by CRISPR-associated phosphodiesterases or a SAM-AMP lyase, potentially providing an 'off switch' analogous to cyclic oligoadenylate-specific ring nucleases<sup>10</sup>. SAM-AMP thus represents a new class of second messenger for antiviral signalling, which may function in different roles in diverse cellular contexts.

Medical subject headings